Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950234 · ClinicalTrials.gov registry record · Phase 2
ACTH in Progressive Forms of MS
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01950234 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 59 participants.
The verdict
NCT01950234, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting of injections on three consecutive days per month in patients with progressive forms of Multiple Sclerosis (MS). Patients will be randomly assigned to either an ACTH arm or a placebo arm. The main hypotheses are that 1) pulsed ACTH will be safe and well-tolerated, and 2) pulsed ACTH will slow progression of clinical and paraclinical measures of MS progression compared to placebo.
Interventions
- DRUG Placebo
- DRUG ACTH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-04-17 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01950234
The ClinicalTrials.gov registry entry for NCT01950234 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01950234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01950234 about?
NCT01950234 is a clinical study titled "ACTH in Progressive Forms of MS". This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting of injections on three consecutive days per month in patients with pro...
What is the current status of trial NCT01950234?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2014-04-17. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT01950234?
The interventions under investigation include: Placebo (DRUG), ACTH (DRUG).
Who is sponsoring clinical trial NCT01950234?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.